Corporate Strategy


Corporate Plans

Physicians with an investigational new drug application (IND)

Clinical trial / Joint Venture

Research Summaries from the National Institutes of Health (NIH) Thalidomide Workshop

Press Releases



Thalidomide is a proven immunosuppressive, an effective antiangiogenic agent and inhibits the body's production of TNF-a.

We are seeking a partner to conduct a clinical trial that would eventually lead to filing an NDA. Preliminary scientific data indicates that this product is effective in treating a number of disease states, including Crohn's Disease, Systemic Lupus, Cancer, Rheumatoid Arthritis and AIDS Wasting. There may be an opportunity to receive Orphan Drug Status for other disease states.

WARNING: Thalidomide is a teratogen. If taken during pregnancy, it can cause severe birth defects or death to an unborn child.

parajumpers outlet beats by dre pas cher sac lv pas cher Discount Chanel bags cheap kate spade bags fake watches Cheap Canada Goose canada goose pas cher canada goose soldes Canada Goose femme pas cher Canada Goose femme soldes replica watches rolex replica